These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 32718086)

  • 21. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
    Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
    Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
    Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
    Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis.
    Fleischer S; Ries S; Shen P; Lheritier A; Cazals F; Burmester GR; Dörner T; Fillatreau S
    Eur J Immunol; 2018 Jan; 48(1):194-203. PubMed ID: 28850672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.
    Yoshizaki K; Nishimoto N; Mihara M; Kishimoto T
    Springer Semin Immunopathol; 1998; 20(1-2):247-59. PubMed ID: 9836380
    [No Abstract]   [Full Text] [Related]  

  • 27. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rheumatoid arthritis and cytokines].
    Kaneko S; Kondo Y; Yokosawa M; Sumida T
    Nihon Rinsho; 2016 Jun; 74(6):913-8. PubMed ID: 27311178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
    Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.
    Kragstrup TW; Andersen T; Heftdal LD; Hvid M; Gerwien J; Sivakumar P; Taylor PC; Senolt L; Deleuran B
    Front Immunol; 2018; 9():2226. PubMed ID: 30319661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside.
    Liu X; Teichtahl AJ; Wicks IP
    Curr Pharm Des; 2015; 21(17):2187-97. PubMed ID: 25760299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
    Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
    Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists.
    Jazayeri JA; Carroll GJ; Vernallis AB
    Int Immunopharmacol; 2010 Jan; 10(1):1-8. PubMed ID: 19804846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.
    Choy EHS; Calabrese LH
    Rheumatology (Oxford); 2018 Nov; 57(11):1885-1895. PubMed ID: 29186541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatoid arthritis: new monoclonal antibodies.
    Serio I; Tovoli F
    Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy in rheumatoid arthritis.
    Köller MD
    Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular targets of rheumatoid arthritis.
    Okamoto H; Hoshi D; Kiire A; Yamanaka H; Kamatani N
    Inflamm Allergy Drug Targets; 2008 Mar; 7(1):53-66. PubMed ID: 18473901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
    Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution].
    Sany J
    C R Biol; 2006 Apr; 329(4):228-40. PubMed ID: 16644493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.